Debate erupts over Quail Hollow's character ahead of 2025 PGA Championship, with some criticizing course changes and others defending its challenging layout.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
Debate erupts over Quail Hollow's character ahead of 2025 PGA Championship, with some criticizing course changes and others defending its challenging layout.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.